+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Heparin Market 2019-2025

  • ID: 5129732
  • Report
  • May 2020
  • Region: Global
  • Orion Market Research Private Limited
UP TO OFF
until Mar 31st 2021

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • B Barun Melsungen AG
  • Eisai Co. Ltd.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Mylan N.V.
  • Opocrin S.P.A
Heparin Market Size, Share & Trends Analysis Report, by Product (Unfractionated Heparin, Low Molecular Weight Heparin and Ultra-Low Molecular Weight Heparin), by Route of Administration (Intravenous and Subcutaneous), by Application (Atrial Fibrillation & heart Attack, Coronary Heart Disease, Pulmonary Embolism, Deep Vein Thrombosis and Others) and Forecast Period, 2019-2025.

The global heparin market is estimated to grow significantly during the forecast period. The major factors encouraging market growth include the increasing prevalence of cardiovascular disorder and venous thromboembolism. Additionally, an increasing number of surgeries due to the high incidence of accidents and Injuries are anticipated to propel the growth of the market. Heparin is an anticoagulant or blood thinner used to prevent blood clotting and essential medication in the treatment of any surgery or heart attacks in order to reduce the risk of errors in treatments.

Many Pharmaceutical companies have launched various heparin related drugs for the treatment of venous thromboembolism and cardiovascular surgery. For instance, in April 2019, B. Braun Medical Inc. announced its launch of Heparin Sodium Injection, USP. It is an FDA approved and first of its kind syringe with attached needle for subcutaneous and intravenous use. It is designed with an aim to provide their patients with a better treatment experience with reduced risk of errors and expanding its product portfolio in the US in the medical field.

The global heparin market is segmented based on the product, route of administration and application. Based on the product, the market is classified into unfractionated heparin, low molecular weight heparin and ultra-low molecular weight heparin. Based on the route of administration, the market is classified into intravenous and subcutaneous. Based on the application, the market is classified into atrial fibrillation & heart attack, coronary heart disease, pulmonary embolism, deep vein thrombosis and others. Geographically, the global heparin market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is estimated to dominate the market owing to the significant prevalence of the cardiovascular disorder.

The major players in the global heparin market include B Barun Melsungen AG, Baxter International Inc., Eisai Co. Ltd., F. Hoffman-La Roche Ltd., Fresenius Kabi AG, Mylan N.V., Novartis AG, Pfizer Inc., and Sanofi S.A. The strategies followed by the market players include mergers and acquisitions, partnerships and collaborations and geographical expansion to expand market share across the globe.

Research Methodology

The market study of the global heparin market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Authentic public databases
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report is intended for drug manufacturers, suppliers, and distributors and government agencies for overall market analysis and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:
  • Global Heparin Market Research and Analysis by Product
  • Global Heparin Market Research and Analysis by Route of Administration
  • Global Heparin Market Research and Analysis by Application
The Report covers:
  • Comprehensive research methodologies of the global heparin market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global heparin market.
  • Insights about market determinants which are stimulating the global heparin market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • B Barun Melsungen AG
  • Eisai Co. Ltd.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Mylan N.V.
  • Opocrin S.P.A
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Baxter International, Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. B Barun Melsungen AG
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Pfizer, Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Sanofi S.A.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Novartis AG
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments

4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities

5. Market Segmentation
5.1. Global Heparin Market by Product
5.1.1. Unfractionated Heparin
5.1.2. Low molecular weight Heparin (LMWH)
5.1.3. Ultra-Low Molecular Weight Heparin (ULMWH)
5.2. Global Heparin Market by Route of Administration
5.2.1. Intravenous
5.2.2. Subcutaneous
5.3. Global Heparin Market by Application
5.3.1. Atrial Fibrillation & Heart Attack
5.3.2. Coronary Artery Disease
5.3.3. Pulmonary Embolism(PE)
5.3.4. Deep Vein Thrombosis (DVT)
5.3.5. Others (Stroke)

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. B Barun Melsungen AG
7.2. Baxter International Inc.
7.3. Eisai Co. Ltd.
7.4. F. Hoffman-La Roche Ltd.
7.5. Fresenius Kabi AG
7.6. GlaxoSmithKline plc
7.7. Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
7.8. Hikma Pharmaceuticals PLC
7.9. Leo Pharma A/S
7.10. Mylan N.V.
7.11. Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd.
7.12. Novartis AG
7.13. Opocrin S.P.A
7.14. Pfizer Inc.
7.15. Sanofi S.A.
7.16. Syntex S.A.
Note: Product cover images may vary from those shown
  • B Barun Melsungen AG
  • Baxter International Inc.
  • Eisai Co. Ltd.
  • F. Hoffman-La Roche Ltd.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • Hikma Pharmaceuticals PLC
  • Leo Pharma A/S
  • Mylan N.V.
  • Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd.
  • Novartis AG
  • Opocrin S.P.A
  • Pfizer Inc.
  • Sanofi S.A.
  • Syntex S.A.
Note: Product cover images may vary from those shown
Adroll
adroll